CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The RESOLVE Consortium aims to validate measurable residual disease as a treatment-guiding biomarker for acute myeloid and chronic lymphocytic leukemia. By establishing a patient registry and conducting a multi-national trial, the project seeks to enhance treatment personalization and improve patient outcomes.
Measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) has strong prognostic value in patients with the most frequent acute and chronic leukemias, acute myeloid (AML) and chronic lymphocytic leukemia (CLL), but it has not yet been confirmed as a treatment-guiding biomarker.
The RESOLVE Consortium will leverage numerous existing expert networks and patient advocacy partnerships to establish the predictive value of MRD in AML/CLL patients, with the expectation that this…
MARTIN-LUTHER-UNIVERSITAT HALLE-WITTENBERG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Amsterdam
Type: Research institute
Activity type: Research Organisations
SME: No
EUROPEAN RESEARCH INITIATIVE ON CLL EV
Germany, Koln
Type: Research institute
Activity type: Research Organisations
SME: No
Italy, RAVENNA
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
